Core Viewpoint - The announcement details a change in shareholding by major shareholder Wang Haibo, who has reduced his stake in Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. to 5% through a planned share reduction, which does not trigger a mandatory takeover bid [1][2]. Summary by Sections 1. Basic Information of the Shareholder - Wang Haibo is a Chinese national and holds permanent residency in Hungary [1]. 2. Details of the Shareholding Change - Wang Haibo reduced his shareholding from 56,099,327 shares (5.41%) to 51,828,605 shares (5.00%) by selling 4,270,722 shares through centralized bidding from July 14 to July 15, 2025 [1]. - The reduction in shareholding does not affect the control of the company as there is no controlling shareholder or actual controller [1][2]. 3. Shareholding Status Before and After the Change - Before the change: Wang Haibo held 56,099,327 shares (5.41% of total share capital) - After the change: Wang Haibo holds 51,828,605 shares (5.00% of total share capital) [1]. 4. Compliance with Regulations - The shareholding change complies with relevant regulations and does not violate any laws or guidelines regarding shareholder reductions [3].
复旦张江: 复旦张江关于持股5%以上股东权益变动至5%的提示性公告